US-based Sequel Med Tech has introduced its Tidepool-powered twiist automated insulin delivery (AID) system across the country. Following clearance by the US Food and Drug Administration (FDA) in 2024 ...

Sequel Med Tech has announced broad national availability of its twist Automated Insulin Delivery (AID) System powered by Tidepool, following clearance by the U.S. Food and Drug Administration in 2024 ...

With nationwide availability now underway, twiist reaches a meaningful milestone in Sequel’s mission to empower the diabetes community with more choice and a more personalized, customizable AID ...

Sequel Med Tech today announced the broad availability of its twiist automated insulin delivery system in the U.S.

Sequel Med Tech and Senseonics have announced a collaboration to integrate Sequel’s twiist Automated Insulin Delivery (AID) System with Senseonics’ Eversense 365 one-year Continuous Glucose Monitoring ...

MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (SENS) ...

Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.

twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H.